loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in On the Move Capricor jumps as study shows longer-term effects of deramiocel Sep 29, 2026, 9:24 PM ETCapricor Therapeutics, Inc. (CAPR) StockBy : Rob Williams, SA News Editor Capricor Therapeutics (CAPR) shares surged in late trading Tuesday as investors reacted to new data on deramiocel, the biotech company's experimental treatment for Duchenne muscular dystrophy, made available as part of the 31st Annual Congress of the World Muscle Society in To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Quick Insights Recent 24-month HOPE-3 data, now included in the regulatory submission, offer longer-term evidence supporting deramiocel, which is significant as the FDA reviews the drug's benefit-risk profile despite lingering uncertainties from the advisory committee. Deramiocel slowed deterioration in upper-limb function by 54% compared to placebo; two-year outcomes versus natural history offer benchmarks showing benefit over expected progression in untreated patients. StealthX exosome programs are in preclinical stages and showcase Capricor's pipeline diversification, with engineered muscle-targeting vesicles potentially offering new treatment approaches for Duchenne and Pompe.
document fetched 2026-09-30 03:01 · canonical https://seekingalpha.com/news/4648315-capricor-jumps-as-study-shows-longer-term-effects-of-deramiocel?feed_item_type=news